Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A

Autor: Mahlangu, Johnny, Kaczmarek, Radoslaw, von Drygalski, Annette, Shapiro, Susan, Chou, Sheng-Chieh, Ozelo, Margareth C, Kenet, Gili, Peyvandi, Flora, Wang, Michael, Madan, Bella, Key, Nigel S, Laffan, Michael, Dunn, Amy L, Mason, Jane, Quon, Doris V, Symington, Emily, Leavitt, Andrew D, Oldenburg, Johannes, Chambost, Hervé, Reding, Mark T, Jayaram, Kala, Yu, Hua, Mahajan, Reena, Chavele, Konstantia-Maria, Reddy, Divya B, Henshaw, Joshua, Robinson, Tara M, Wong, Wing Yen, Pipe, Steven W, GENEr8-1 Trial Group, Hermans, Cédric
Přispěvatelé: UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre de malformations vasculaires congénitales
Rok vydání: 2023
Předmět:
Zdroj: The New England journal of medicine, Vol. 388, no.8, p. 694-705 (2023)
ISSN: 1533-4406
0028-4793
DOI: 10.1056/nejmoa2211075
Popis: BACKGROUND: Valoctocogene roxaparvovec delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated virus vector to prevent bleeding in persons with severe hemophilia A. The findings of a phase 3 study of the efficacy and safety of valoctocogene roxaparvovec therapy evaluated after 52 weeks in men with severe hemophilia A have been published previously. METHODS: We conducted an open-label, single-group, multicenter, phase 3 trial in which 134 men with severe hemophilia A who were receiving factor VIII prophylaxis received a single infusion of 6×1013 vector genomes of valoctocogene roxaparvovec per kilogram of body weight. The primary end point was the change from baseline in the annualized rate of treated bleeding events at week 104 after receipt of the infusion. The pharmacokinetics of valoctocogene roxaparvovec were modeled to estimate the bleeding risk relative to the activity of transgene-derived factor VIII. RESULTS: At week 104, a total of 132 participants, including 112 with data that were prospectively collected at baseline, remained in the study. The mean annualized treated bleeding rate decreased by 84.5% from baseline (P
Databáze: OpenAIRE
Externí odkaz: